Phospholamban ablation in hearts expressing the high affinity SERCA2b isoform normalizes global Ca2+ homeostasis but not Ca2+-dependent hypertrophic signaling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 12, 2012, Pages 2574-2582

  Louch, William E ^a,b,c   Vangheluwe, Peter ^d   Bito, Virginie ^a   Raeymaekers, Luc ^d   Wuytack, Frank ^d   Sipido, Karin R ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

Cardiac hypertrophy; Cardiomyocyte Ca2+ homeostasis; Phospholamban ablation

Indexed keywords

CAFFEINE; CALCIUM CHANNEL L TYPE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2B; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; FUNCTIONAL STATUS; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE RELAXATION; HEART PACING; HEART VENTRICLE REMODELING; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION;

ANIMALS; CALCIUM; CALCIUM SIGNALING; CALCIUM-BINDING PROTEINS; CARDIOMEGALY; HEART FAILURE; HOMEOSTASIS; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 84862524422     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01166.2011     Document Type: Article

References (37)

1. 2+ exchange currents. J Physiol 589: 2569-2583, 2011.
2. Andersson KB, Birkeland JA, Finsen AV, Louch WE, Sjaastad I, Wang Y, Chen J, Molkentin JD, Chien KR, Sejersted OM, Chris-tensen G. Moderate heart dysfunction in mice with inducible cardiomyo-cyte-specific excision of the Serca2 gene. J Mol Cell Cardiol 47:180-187, 2009.
3. 2+]i transients in mouse ventricular myocytes. J Physiol 543: 889-898, 2002.
4. 2+ loads only. Circ Res 92: 881-887, 2003.
5. Chen X, Nakayama H, Zhang X, Ai X, Harris DM, Tang M, Zhang H, Szeto C, Stockbower K, Berretta RM, Eckhart AD, Koch WJ, Molkentin JD, Houser SR. Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy. J Mol Cell Cardiol 50: 460-470, 2011.
6. Cheng H, Lederer WJ, Cannell MB. Calcium sparks: elementary events underlying excitation-contraction coupling in heart muscle. Science 262: 740-744, 1993.
7. Dash R, Kadambi V, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW, Kranias EG. Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103: 889-896, 2001.
8. 2+-ATPase in a rat model of heart failure. Circulation 104: 1424-1429, 2001.
9. 2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses. J Biol Chem 278: 47877-47889, 2003.
10. Frey N, Richardson JA, Olson EN. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci USA 97: 14632-14637, 2000.
11. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW, MacLennan DH, Kremastinos DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest 111: 869-876, 2003.
12. 2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 100: 380-389, 1997.
13. 2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes. Circ Res 103: 1109-1119, 2008.
14. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Green-berg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ. Calcium upregu-lation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 15: 171-181, 2009.
15. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 97: 533-539, 1996.
16. Lalande S, Johnson BD. Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today (Barc) 44: 503-513, 2008.
17. Li L, Louch WE, Niederer SA, Andersson KB, Christensen G, Sejersted OM, Smith NP. Calcium dynamics in the ventricular myocytes of SERCA2 knockout mice: A modeling study. Biophys J 100: 322-331, 2011.
18. 2+ and its effects on energetics and redox balance in normal and failing heart. J Bioenerg Biomembr 41: 127-132, 2009.
19. Louch WE, Hougen K, Mork HK, Swift F, Aronsen JM, Sjaastad I, Reims HM, Roald B, Andersson KB, Christensen G, Sejersted OM. Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout. J Physiol 588: 465-478, 2010.
20. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doet-schman T, Kranias EG. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75: 401-409, 1994.
21. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 4: 566-577, 2003.
22. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Martone ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99: 313-322, 1999.
23. 2+ uptake to improve heart failure: hit or miss. Circ Res 106: 230-233, 2010.
24. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW, Kranias EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest 111: 859-867, 2003.
25. Trafford AW, Diaz ME, Eisner DA. A novel, rapid and reversible method to measure Ca buffering and time-course of total sarcoplasmic reticulum Ca content in cardiac ventricular myocytes. Pflügers Arch 437: 501-503, 1999.
26. 2+ transport ATPase isoforms SERCA2a and SERCA2b are targeted to the same sites in the murine heart. Cell Calcium 34: 457-464, 2003.
27. 2+ affinity can lead to severe cardiac hypertrophy, stress intolerance and reduced life span. J Mol Cell Cardiol 41: 308-317, 2006.
28. 2+-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart. Circ Res 89: 838-846, 2001.
29. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 322: 1178-1191, 2004.
30. 2+. Am J Physiol Cell Physiol 271: C391-C397, 1996.
31. 2+-ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents. J Clin Invest 119: 976-985, 2009.
32. Yang J, Rothermel B, Vega RB, Frey N, McKinsey TA, Olson EN, Bassel-Duby R, Williams RS. Independent signals control expression of the calcineurin inhibitory proteins MCIP1 and MCIP2 in striated muscles. Circ Res 87: E61-E68, 2000.
33. Yao A, Su Z, Dillmann WH, Barry WH. Sarcoplasmic reticulum function in murine ventricular myocytes overexpressing SR CaATPase. J Mol Cell Cardiol 30: 2711-2718, 1998.
34. Zhai J, Schmidt AG, Hoit BD, Kimura Y, MacLennan DH, Kranias EG. Cardiac-specific overexpression of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo. J Biol Chem 275: 10538-10544, 2000.
35. 2+ handling but exacerbates cardiac dysfunction in CaMKI-Idelta(C) transgenic mice. Circ Res 106: 354-362, 2010.
36. Zhao W, Uehara Y, Chu G, Song Q, Qian J, Young K, Kranias EG. Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. J Mol Cell Cardiol 37: 607-612, 2004.
37. Zvaritch E, Backx PH, Jirik F, Kimura Y, de LS, Schmidt AG, Hoit BD, Lester JW, Kranias EG, MacLennan DH. The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility. J Biol Chem 275: 14985-14991, 2000.